• Ahmed Hamedjwied Ataimish Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad-Iraq
  • Nadan. Al-shawi Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad-Iraq
  • Mohammed M. Al-qurtas Al-Kindy College of Medicine, University of Baghdad, Baghdad-Iraq


1, 2 Dimethylhydrazines, 5-Flurouracil, Pentoxifylline, Sildenafil, Colorectal carcinoma, Carcinoembryonic antigen, carbohydrate antigen, Caspase-3


Objective: This study was designed to investigate some possible therapeutic mechanisms of pentoxifylline and sildenafil in the treatment of colorectal carcinoma induced by 1, 2 dimethylhydrazines in rats.

Methods: Rats were allocated into seven groups, negative control, colon cancer induced by 1,2,dimethylhydrazine, 5-fluorouracil (5-FU) (50 mg/kg)-treated, pentoxifylline (PTX) (50 mg/kg)-treated, sildenafil (0.7 mg/kg)-treated groups; the two other groups set as colon cancer induced group treated with PTX (50 mg/kg) plus 5-FU(50 mg/kg) and sildenafil (0.7 mg/kg) plus 5-FU (50 mg/kg), respectively.

Results: Biochemical results revealed significant elevation of serum carcinoembryonic antigen (CEA) levels, carbohydrate19-9 antigen (CA19-9) as colon cancer specific antigen markers; and a significant decrease in scaspase-3 (CASP3) as a marker for apoptosis, in the cancer-induced group compared to negative control group. Cancer-induced rats treated with 5-FU, with PTX or sildenafil showed a significant decrease in serum CEA and CA19-9 levels and a significant increase in CASP3 levels compared to cancer induced group. Furthermore, plasma levels of CEA and CA19-9 in 5-FU plus pentoxifylline and in 5-FUplus sildenafil groups were significantly decreased and plasma levels of CASP3 in 5-FU plus PTX, 5-FU plus sildenafil groups were significantly increased with respect to 5-FU treated group.

Conclusion: Results of the present study suggest a good therapeutic approach of the PDE inhibitors, PTX and sildenafil for intervention against progressive colon cancer with special reference to the induction of apoptosis in colon cancer cells.



Download data is not yet available.


Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.

Wingo PA, Ries LA, Parker SL, Heath CW Jr. Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev 1998;7:271-82.

Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001;51:15-36.

Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002;3:166-74.

Graham J, Mushin M, Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discovery 2004;1:11-2.

Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.

Rigau J, Pique JM, Rubio E, Planas R, Planas R, Tarrech JM, et al. Effects of long-termsulindac therapy on colonic polyposis. Ann Intern Med 1991;115:952-4.

Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.

Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Martucci C, et al. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998;19:87-91.

Bender AT, Beavo J. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520.

Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 2001;65:1-52.

Pusztai L, Zhen JH, Arun B, Rivera E, Whitehead C, Thompson WJ, et al. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 2003;21:3454-61.

Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L, et al. Exisulind, novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 2001;61:3961-8.

Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC, et al. Exisulindinduced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2003;2:479-88.

Spoto G, Fioroni M, Rubini C. Cyclic guanosine monophosphate phosphodiesterase activity in human gingival carcinoma. J Oral Pathol Med 2003;32:189-94.

Zhu B, Strada SJ. The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr Top Med Chem 2007;7:437-54.

Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 2003;101:265-9.

Abadi AH, Gary BD, Tinsley HN, Piazza GA, Abdel-Halim M. Synthesis, molecular modeling and biological evaluation of novel tadalafilanalogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective. Eur J Med Chem 2010;45:1278-86.

Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013;37:845-54.

Aviado DM, Dettelbach HR. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology 1984;35:407-17.

Okunieff P, Augustine E, Hicks JE, Cornelison TL, Altemus RM, Naydich BG, et al. Pentoxifylline in the treatment of radiation-induced fibrosis. J Clin Oncol 2004;22:2207-13.

Theis VS, Sripadam R, Ramani V, Lal S. Chronic radiation enteritis. Clin Oncol 2010;22:70-83.

Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impotence Res 1996;8:47-52.

Ballard SA, Gingell CJ, Tan KIM, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998;159:2164-71.

Rashid A. The efficacy and safety of PDE5 inhibitors. Clinical Cornerstone 2005;7:47-55.

Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science 1992;257:401-3.

Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Eng J Med 1993;329:2002.

Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when co-prescribed in pulmonary hypertension. Br J Clin Pharmacol 2005;60:107-12.

Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005;111:1601-10.

Angel CA, Pratt CB, Rao BN, Schell MJ, Parham DM, Lobe TE, et al. Carcinoembryonic antigen and carbohydrate 19-9 antigen as markers for colorectal carcinoma in children and adolescents. Cancer 1992;69:1487-91.

Atkinson BF, Ernst CS, Herlyn M, Seplewski Z, Sears HF, Koprwoski H. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res 1982;42:4820-3.

Arends JW, Verstynen C, Bosman FT, Hilgers J, Steplewski Z. Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma 1983;2:219-29.

Kannagi R. Carbohydrate antigen sialyllewisa-its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J 2007;30:189-209.

Von Kleist S, Hesse Y, Kananeeh H. Comparative evaluation of tumor markers, Ca 242, CA 19-9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996;16:2325-31.

Hou Y, Gupta N, Schoenlein P, Wong E, Martindale R, Ganapathy V, et al. An anti-tumor role for cGMP-dependent protein kinase. Cancer Lett 2006;240:60-8.

Bird RP, Good CK. The significance of aberrant cryptfoci in understanding the pathogenesis of colon cancer. Toxicol Lett 2000;112-113:395-402.

Ermens AA, Kroes AC, Lindemans J, Abels J. 5-Fluorouracil treatment of rat leukemia and a reappraisal of its application in human leukemia. Anticancer Res 1986;6:797-800.

Honess DJ. Pentoxifylline-a modifier of blood cell deformability as a radiosensitive in a murine tumour. Br J Radiol 1991;65:358.

Kolettis TM, Kontaras K, Spartinos I, Maniotis C, Varnavas V, Koutouzis M, et al. Dose-dependent effects of sidenafil on post-ischaemic left ventricular function in the rat isolated heart. J Pharm Pharmacol 2010;62:346-51.

Rehmann H, Wittinghofer A, Bos JL. Capturing cyclic nucleotides in action: snapshots from crystallographic studies. Nat Rev Mol Cell Biol 2007;8:63-73.

Pitari GM, Di Guglielmo MD, Park J, Schulz S, Waldman SA. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci 2001;98:7846-51.

Zhou B, Li F, Chen H, Song J. The modulation of apoptosis by cyclic AMP involves Akt and epidermal growth factor receptor. Int J Biochem Cell Biol 2005;37:1483-95.

Pertuit M, A Barlier, Enjalbert A, Gerard C. Signaling pathway alterations in pituitary adenomas: involvement of Gsalpha, cAMP and mitogen-activated protein kinases. J Neuroendocrinol 2009;21:869-77.

Kwon IK, R Wang, Thangaraju M, Shuang H, Liu K, Dashwood R, et al. PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4. Oncogene 2010;29:3423-34.

Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007;44:151-78.

Thomas SN, Zhu F, Schnaar RL, Alves CS, Konstantopoulos K. Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E-and L-selectin in shear flow. J Biol Chem 2008;283:15647-55.

Konstantopoulos K, Thomas SN. Cancer cells in transit: the vascular interactions of tumor cells. Annu Rev Biomed Eng 2009;11:177-202.

Thomas SN, Tong Z, Stebe KJ, Konstantopoulos K. Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnostic. Biorheology 2009;46:207-25.

Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.

Makin G. Targeting apoptosis in cancer chemotherapy. Expert Opin Ther Targets 2002;6:73-84.

Soh JW, Mao Y, Kim MG, Pamukcu R, Li H, Piazza GA, et al. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c Jun NH2-terminal kinase 1. Clin Cancer Res 2000;6:4136-41.

Rice PL, Beard KS, Driggers LJ, Ahnen DJ. Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Cancer Res 2004;64:8148-51.

Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y, Piazza GA. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res 2011;4:1275-84.

Li H, Liu L, David ML, Whitehead CM, Chen M, Fetter JR, et al. Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. Biochem Pharmacol 2002;64:1325-36.

Liang Y, O’Driscoll L, McDonnell S, Doolan P, Oglesby I, Duffy K, et al. Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer 2004;111:484-93.

Polekova L, Barancik M, Mrazova T, Pirker R, Wallner J, Sulova Z, et al. Adaptation of mouse leukemia cells L1210 to vincristine. Evidence for expression of P-glycoprotein. Neoplasma 1992;39:73-7.

Drobná Z, Stein U, Walther W, Barancík M, Breier A. Pentoxifylline influences drug transport activity of P-glycoprotein and decreases mdrl gene expression in multidrug resistant mouse leukemic L1210/VCR cells. Gen Physiol Biophys 2002;21:103-9.

Barancik M, Bohacova V, Gibalova L, Sedlak J, Sulova Z, Breier A. Potentiation of anticancer drugs: effects of pentoxifylline on neoplastic cells. Int J Mol Sci 2012;13:369-82.

Rishi L, Gahlot S, Kathania M, Majumdar S. Pentoxifylline induces apoptosis in vitro in cutaneous T cell lymphoma (HuT-78) and enhances FasL mediated killing by upregulating Fas expression. Biochem Pharmacol 2009;77:30-45.

Rauko P, Sedlak J, Duraj J, Szekeres MF, Novotny L. Pentoxifylline stimulates drug-induced apoptosis in leukemiccells. Neoplasma 1998;45:296-300.

Kupsakova I, Rybar A, Docolomansky P, Drobna Z, Stein U, Walther W, et al. Reversal of P-glycoprotein mediated vincristine resistance of L1210/VCR cells by analogues of pentoxifylline. A QSAR study. Eur J Pharm Sci 2004;21:283-93.

Ohsaki Y, Ishida S, Fujikane T, Kikuchi K. Pentoxifylline potentiates the antitumor effect of cisplatin and etoposide on human lung cancer cell lines. Oncology 1996;53:327-33.

Black KL, Yin D, Ong JM, Hu J, Konda BM, Wang X, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 2008;1230:290-302.

Horsman MR. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol 1995;34:571-87.

Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamics and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97.

Lee I, Biaglow JE, Lee J, Cho MJ. Physiological mechanisms of radiation sensitization by pentoxifylline. Anticancer Res 2000;20:4605-9.

Hu J, Ljubimova JY, Inoue S, Konda B, Patil R, Ding H, et al. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One 2010;5:e10108.

Sun YL, Patel A, Kumar P, Chen ZS. Role of ABC transporters in cancer chemotherapy. Chin J Cancer 2012;31:51-7.

Choi YH, Park HY. Anti-inflammatory effects of spermidine in lipopolysaccharide-stimulated BV2 microglial cells. J Biomed Sci 2012;19:31.

Chang CC, Lu WJ, Ong ET, Chiang CW, Lin SC, Huang SY, et al. A novel role of sesamol in inhibiting NF-κB-mediated signaling in platelet activation. J Biomed Sci 2011;18:93.

Yadav VR, Prasad S, Gupta SC, Sung B, Phatak SS, Zhang S, et al. 3-Formylchromone interacts with cysteine 38 in p65 protein and with cysteine 179 in IκBα kinase, leading to down-regulation of nuclear factor-κB (NF-κB)-regulated gene products and sensitization of tumor cells. J Biol Chem 2012;287:245-56.

Bravo-Cuellar A, Ortiz-Lazareno PC, Lerma-Diaz JM, Dominguez-Rodriguez JR, Jave-Suarez LF, Aguilar-Lemarroy A, et al. Sensitization of cervix cancer cells to Adriamycin by Pentoxifylline induces an increase in apoptosis and decrease senescence. Mol Cancer 2010;9:114.

Lerma-Diaz JM, Hernandez-Flores G, Dominguez-Rodriguez JR, Ortiz-Lazareno PC, Gomez-Contreras P, Cervantes-Munguia R, et al. In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline. Involvement of caspase cascades and IκBα phosphorylation. Immunol Lett 2006;103:149-58.

Hernandez-Flores G, Ortiz-Lazareno PC, Lerma-Diaz JM, Dominguez-Rodriguez JR, Jave-Suarez LF, Aguilar-Lemarroy Adel C, et al. Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence. BMC Cancer 2011;11:483.



How to Cite

Ataimish, A. H., N. Al-shawi, and M. M. Al-qurtas. “EVALUATION OF CHEMOPREVENTIVE RESPONSE OF PENTOXIPHYLLINE AND SILDENAFIL IN COLORECTAL CARCINOMA EXPERIMENTALLY INDUCEDIN RATS: COMPARATIVE STUDY WITH 5-FLUOROURACIL”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 12, Dec. 2015, pp. 217-22, https://journals.innovareacademics.in/index.php/ijpps/article/view/8959.



Original Article(s)